Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 14
Submit an article Journal homepage
1,212
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

Scott F. Huntingtona Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT, USAView further author information
,
Beenish S. Manzoorb AbbVie Inc, North Chicago, IL, USAView further author information
,
Justin T. Puckettc COVIA Health Solutions, Lansdale, PA, USAView further author information
,
Sachin Kamal-Bahlc COVIA Health Solutions, Lansdale, PA, USACorrespondence[email protected]
View further author information
,
Hasan Alhasanib AbbVie Inc, North Chicago, IL, USAView further author information
,
Arliene Ravelod Genentech Inc, South San Francisco, CA, USAView further author information
,
Dureshahwar Jawaidb AbbVie Inc, North Chicago, IL, USAView further author information
&
Jalpa A. Doshie Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAView further author information
 show all
Pages 2316-2323 | Received 07 Feb 2023, Accepted 30 Aug 2023, Published online: 21 Sep 2023

References

  • Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3(1):16096. doi:10.1038/nrdp.2016.96
  • Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international society of geriatric oncology (SIOG) task force. Ann Oncol. 2017;28(2):218–227. doi:10.1093/annonc/mdw547
  • Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):368–377. doi:10.1182/asheducation-2015.1.368
  • Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99(6):965–972. doi:10.3324/haematol.2013.096107
  • Gomes LC, Ferrão ALM, Evangelista FCG, et al. Advances in chronic lymphocytic leukemia pharmacotherapy. Biomed Pharmacother. 2018;97:349–358. doi:10.1016/j.biopha.2017.10.105
  • Iovino L, Shadman M. Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape. Curr Treat Options Oncol. 2020;21(4):24.
  • Goodman A. Chronic lymphocytic leukemia new treatments achieve deeper remissions: the ASCO Post. 2020 [cited 2022 Nov 23]. https://ascopost.com/issues/november-10-2020/chronic-lymphocytic-leukemia-new-treatments-achieve-deeper-remissions/
  • Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa1513257
  • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976
  • Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75. doi:10.1016/S1470-2045(17)30909-9
  • Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–376. doi:10.1634/theoncologist.2015-0405
  • Doshi JA, Jahnke J, Raman S, et al. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of medicare beneficiaries. J Manag Care Spec Pharm. 2021;27(10):1457–1468. doi:10.18553/jmcp.2021.27.10.1457
  • Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–2067. doi:10.1182/blood-2014-09-603670
  • Mato AR, Sharman JP, Biondo JML, et al. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. Haematologica. 2022;107(1):134–142. doi:10.3324/haematol.2020.266486
  • Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. doi:10.3324/haematol.2017.182907
  • O'Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib ­discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis. Am J Hematol. 2019;94(5):554–562. doi:10.1002/ajh.25436
  • Eyre TA, Lamanna N, Roeker LE, et al. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica. 2021;106(1):284–287. doi:10.3324/haematol.2019.241539
  • Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020;13(1):66. doi:10.1186/s13045-020-00870-w
  • Bhat SA, Gambril J, Azali L, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood. 2022;140(20):2142–2145. doi:10.1182/blood.2022016953
  • Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa1815281
  • Freed M, Biniek JF, Damico A, et al. Medicare advantage in 2022: enrollment update and key trends: KFF. 2022 [cited 2022 Nov 23]. https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2022-enrollment-update-and-key-trends/

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.